Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents
نویسندگان
چکیده
Monoclonal gammopathies comprise a group of disorders characterized by the neoplastic proliferation of a single clone of plasma cells. Multiple myeloma (MM; plasma-cell myeloma, myelomatosis, Kahler’s disease) is the prototype of monoclonal plasma cell disorders, accounting for 1% of all newly diagnosed cancers and 10% of all hematologic malignancies. It is the second most frequent hematologic malignancy after lymphoma, with an annual incidence of approximately four to five per 100,000 individuals. It afflicts more than 20,000 new people per year, and results in an estimated 10,000 deaths per year in the USA [1].
منابع مشابه
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerl...
متن کاملFront line treatment of elderly multiple myeloma in the era of novel agents
Melphalan combined with prednisone (MP) has long been the historical treatment of reference for a large proportion of elderly myeloma (MM) patients ineligible for autologous stem cell transplantation, and is still the backbone of new regimens that include the new era of novel agents. Melphalan-prednisone-thalidomide (MPT) and melphalan-prednisone-bortezomib (Velcade((R)), MPV), proved superior ...
متن کاملTretatment Approach of Nontransplant Patients with Multiple Myeloma
Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment. In recent years there is a huge improvement in treatment of patients with multiple myeloma. The milestones of these improvement are: autologous transplanta...
متن کاملTreatment options for relapsed and refractory multiple myeloma.
Treatment options for patients with relapsed myeloma have benefited from the development of new targeted agents. The use of bortezomib, thalidomide, and lenalidomide have dramatically changed outcomes for patients with relapsed myeloma. New agents are also in development, on the basis of preclinical rationale, as well as combinations of conventional and novel agents. Together each of these trea...
متن کاملAutologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future
High-dose melphalan (200 mg/m(2)) as conditioning regimen followed by autologous stem cell transplantation (ASCT) rescue has been established as a standard treatment for patients with multiple myeloma (MM) younger than 65 years of age. However, the role of ASCT in elderly patients older than 65 years remains controversial in the era of novel agents such as thalidomide, bortezomib, and lenalidom...
متن کامل